NFL Biosciences SA (ALNFL) Ratios
NFL Biosciences SA Ratios
FR:ALNFL's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, FR:ALNFL's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.17 | 1.27 | 1.06 | 1.46 | 19.16 |
| Quick Ratio | 1.17 | 1.27 | 1.06 | 1.46 | 19.16 |
| Cash Ratio | 0.69 | 0.73 | 0.65 | 0.68 | 16.36 |
| Solvency Ratio | -0.96 | -0.76 | -1.02 | -1.54 | -2.35 |
| Operating Cash Flow Ratio | 0.00 | 0.00 | 0.00 | 0.07 | 0.47 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 1.26 | 12428.57 |
| Net Current Asset Value | $ 48.15K | $ 706.24K | $ 199.84K | $ 706.12K | $ 3.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.01 | 0.02 | 0.03 | 0.02 |
| Debt-to-Equity Ratio | 1.90 | 0.04 | 0.18 | 0.10 | 0.03 |
| Debt-to-Capital Ratio | 0.66 | 0.04 | 0.15 | 0.09 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.59 | 0.02 | 0.10 | 0.07 | 0.00 |
| Financial Leverage Ratio | 11.97 | 3.70 | 11.35 | 2.84 | 1.12 |
| Debt Service Coverage Ratio | -19.88 | -48.78 | -124.94 | -28.55 | -1714.13 |
| Interest Coverage Ratio | -272.89 | -9177.93 | -680.97 | -6112.64 | -1676.33 |
| Debt to Market Cap | 0.04 | 0.00 | 0.01 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.05 | 0.00 | 0.01 | 0.02 | 0.02 |
| Net Debt to EBITDA | 0.38 | 0.71 | 0.56 | 0.35 | 2.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -145963.04% | -28.03% | 0.00% | -1360853.85% |
| EBIT Margin | 0.00% | -5904219.57% | -2052.57% | 0.00% | -2869153.85% |
| EBITDA Margin | 0.00% | -5758256.52% | -2024.54% | 0.00% | -2757612.82% |
| Operating Profit Margin | 0.00% | -6065415.22% | -2215.09% | 0.00% | -2312479.49% |
| Pretax Profit Margin | 0.00% | -5904889.13% | -2055.82% | 0.00% | -2870538.46% |
| Net Profit Margin | 0.00% | -4523563.04% | -1872.64% | 0.00% | -2508317.95% |
| Continuous Operations Profit Margin | 0.00% | -4523563.04% | -1872.63% | 0.00% | -2508315.38% |
| Net Income Per EBT | 86.01% | 76.61% | 91.09% | 85.40% | 87.38% |
| EBT Per EBIT | 99.62% | 97.35% | 92.81% | 94.95% | 124.13% |
| Return on Assets (ROA) | -90.57% | -57.64% | -94.33% | -102.00% | -26.55% |
| Return on Equity (ROE) | -1083.80% | -213.11% | -1070.30% | -289.51% | -29.76% |
| Return on Capital Employed (ROCE) | -522.57% | -285.74% | -1266.03% | -357.05% | -25.77% |
| Return on Invested Capital (ROIC) | -374.78% | -180.34% | -1082.19% | -277.54% | -22.52% |
| Return on Tangible Assets | -94.63% | -60.06% | -97.80% | -108.13% | -27.47% |
| Earnings Yield | -22.19% | -10.74% | -32.08% | -23.76% | -7.79% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 |
| Payables Turnover | 4.94 | 1.35 | 0.03 | 1.88 | 4.42 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 22.08 | 0.00 | 0.02 |
| Asset Turnover | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.44 | 0.00 | 0.00 |
| Cash Conversion Cycle | -73.91 | 8397506.29 | -12064.65 | -193.79 | 2058348.90 |
| Days of Sales Outstanding | 0.00 | 8397777.17 | 2023.19 | 0.00 | 2058431.54 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 73.91 | 270.89 | 14087.84 | 193.79 | 82.64 |
| Operating Cycle | 0.00 | 8397777.17 | 2023.19 | 0.00 | 2058431.54 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Free Cash Flow Per Share | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 1.26 | 1.02 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 2230.77 |
| Free Cash Flow Yield | 0.00% | 0.00% | 0.00% | 1.02% | 0.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.54 | -9.31 | -3.12 | -4.21 | -12.84 |
| Price-to-Sales (P/S) Ratio | 0.00 | 421000.26 | 58.37 | 0.00 | 322129.97 |
| Price-to-Book (P/B) Ratio | 48.85 | 19.83 | 33.36 | 12.19 | 3.82 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | 0.00 | 0.00 | 98.07 | 144.40 |
| Price-to-Operating Cash Flow Ratio | 0.00 | 0.00 | 0.00 | 98.07 | 144.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.19 | 0.17 | 1.46 | -0.03 | -0.05 |
| Enterprise Value Multiple | -3.60 | -6.60 | -2.32 | -3.32 | -8.93 |
| Enterprise Value | 13.54M | 17.49M | 9.40M | 9.32M | 9.61M |
| EV to EBITDA | -3.60 | -6.60 | -2.32 | -3.32 | -8.93 |
| EV to Sales | 0.00 | 380292.70 | 46.99 | 0.00 | 246371.94 |
| EV to Free Cash Flow | 0.00 | 0.00 | 0.00 | 88.82 | 110.44 |
| EV to Operating Cash Flow | 0.00 | 0.00 | 0.00 | 88.82 | 110.44 |
| Tangible Book Value Per Share | 0.01 | 0.08 | 0.03 | 0.14 | 0.60 |
| Shareholders’ Equity Per Share | 0.02 | 0.10 | 0.04 | 0.16 | 0.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.14 | 0.23 | 0.09 | 0.15 | 0.13 |
| Revenue Per Share | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Net Income Per Share | -0.26 | -0.21 | -0.46 | -0.47 | -0.19 |
| Tax Burden | 0.86 | 0.77 | 0.91 | 0.85 | 0.87 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 59087.26 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.00 | 0.00 | -0.04 | -0.09 |
Currency in EUR
